Revance Therapeutics

$22.71 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.

Stock Analysis

last close $22.71
1-mo return -14.4%
3-mo return -22.7%
avg daily vol. 811.57T
52-week high 33.83
52-week low 19.51
market cap. $1.9B
forward pe -
annual div. -
roe -137.3%
ltg forecast -
dividend yield -
annual rev. $47M
inst own. 89%
baraka

Subscribe now for daily local and international financial news

Subscribe